News Releases

Webcast

Q1 2021 AtriCure, Inc. Earnings Conference Call

04/27/21 4:30 PM EDT

Webcast Presentation

Click here for webcast

Webcast

AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

03/16/21 1:10 PM EDT

Webcast Presentation

Click here for webcast

Webcast

AtriCure at the SVB Leerink 10th Annual Global Healthcare Conference

02/24/21 8:00 AM EST

Webcast Presentation

Click here for webcast

Webcast

Q4 and Full Year 2020 AtriCure, Inc. Earnings Conference Call

02/23/21 4:30 PM EST

Webcast Presentation

Click here for webcast

Webcast

CONVERGE Trial Results – Investor and Analyst Discussion

05/08/20 1:00 PM EDT

Webcast Presentation

Click here for webcast

Date	Title
04/08/21	AtriCure Names B. Kristine Johnson Board Chair MASON, Ohio --(BUSINESS WIRE)--Apr. 8, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair.
04/06/21	AtriCure to Announce First Quarter 2021 Financial Results MASON, Ohio --(BUSINESS WIRE)--Apr. 6, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021 .
03/02/21	AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference MASON, Ohio --(BUSINESS WIRE)--Mar. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31 st Annual
02/23/21	AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results MASON, Ohio --(BUSINESS WIRE)--Feb. 23, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results.
02/10/21	AtriCure to Participate at the SVB Leerink 10th Annual Global Healthcare Conference MASON, Ohio --(BUSINESS WIRE)--Feb. 10, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 10 th Annual
02/02/21	AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results MASON, Ohio --(BUSINESS WIRE)--Feb. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday,
01/11/21	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020 Fourth quarter 2020 worldwide revenue of $57.7 million ( U.S. $47.4 million , International $10.3 million ) MASON, Ohio --(BUSINESS WIRE)--Jan. 11, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management,
01/04/21	AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy Expansion includes adolescent patients, as young as 12 years of age, who can benefit from cryo nerve block therapy during surgical procedures involving the chest wall. MASON, Ohio --(BUSINESS WIRE)--Jan. 4, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial

Search form

News Releases

Keyword Search